Cargando…
Targeting CD44 Receptor Pathways in Degenerative Joint Diseases: Involvement of Proteoglycan-4 (PRG4)
Rheumatoid arthritis (RA), osteoarthritis (OA), and gout are the most prevalent degenerative joint diseases (DJDs). The pathogenesis underlying joint disease in DJDs remains unclear. Considering the severe toxicities reported with anti-inflammatory and disease-modifying agents, there is a clear need...
Autor principal: | Qadri, Marwa M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10609794/ https://www.ncbi.nlm.nih.gov/pubmed/37895896 http://dx.doi.org/10.3390/ph16101425 |
Ejemplares similares
-
The interaction of lubricin/proteoglycan 4 (PRG4) with toll-like receptors 2 and 4: an anti-inflammatory role of PRG4 in synovial fluid
por: Alquraini, Ali, et al.
Publicado: (2015) -
Proteoglycan 4 (PRG4) treatment enhances wound closure and tissue regeneration
por: Krawetz, Roman J., et al.
Publicado: (2022) -
Recombinant human PRG4 (rhPRG4) suppresses breast cancer cell invasion by inhibiting TGFβ-Hyaluronan-CD44 signalling pathway
por: Sarkar, Anusi, et al.
Publicado: (2019) -
The autocrine role of proteoglycan-4 (PRG4) in modulating osteoarthritic synoviocyte proliferation and expression of matrix degrading enzymes
por: Alquraini, Ali, et al.
Publicado: (2017) -
Quadruped Gait and Regulation of Apoptotic Factors in Tibiofemoral Joints following Intra-Articular rhPRG4 Injection in Prg4 Null Mice
por: Yang, Daniel S., et al.
Publicado: (2022)